by Mark Chiang

马克·蒋

Share To

分享到

Bayer has received approval from the U.S. Food and Drug Administration (FDA) for an expanded use of its drug Kerendia, a mineralocorticoid receptor antagonist (MRA), to treat heart failure. This new indication is considered a significant development for the medication, with potential implications for its market performance..

拜耳公司已获得美国食品药品监督管理局（FDA）对其药物Kerendia（一种矿物皮质激素受体拮抗剂，MRA）扩大使用范围的批准，用于治疗心力衰竭。这一新适应症被认为是该药物的一项重要进展，可能对其市场表现产生影响。

The FDA’s decision allows Kerendia to be used in patients with heart failure, broadening its therapeutic scope beyond its previous indications. The approval highlights the drug’s role in addressing a condition that affects millions of individuals worldwide. Bayer has positioned Kerendia as a key product in its portfolio, and this regulatory milestone is expected to enhance its clinical utility and commercial prospects..

FDA的决定允许Kerendia用于心力衰竭患者，拓宽了其治疗范围，超越了之前的适应症。此次批准突显了该药物在应对全球数百万人受影响的疾病中的作用。拜耳已将Kerendia定位为其产品组合中的关键产品，这一监管里程碑预计将提升其临床应用价值和商业前景。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: July 14, 2025

日期：2025年7月14日

Related posts:

相关内容：

Generic Drug Makers Balance Profitability with Affordability Through Market Research & Adaptable Pricing Strategies

通用药物制造商通过市场研究和灵活的定价策略，在盈利能力与可负担性之间取得平衡。

Critical Hub for Logical Thinking Identified

逻辑思维的关键枢纽被识别出来

Study Finds Taurine Levels Increase With Age, Challenging Anti-Aging Supplement Claims

研究发现牛磺酸水平随年龄增长而增加，挑战抗衰老补充剂的说法

PDA/ANSI Standard 06-2025 Released in February 2025 to Guide Quality Culture Assessments

PDA/ANSI标准06-2025于2025年2月发布，用于指导质量文化评估

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

[email protected]

Author

作者

Mark Chiang

马克·蒋

Related Post

相关文章

News Flash

新闻快讯

Sichuan University Study Finds Nighttime Blood Pressure Medication Improves Nocturnal Control

四川大学研究发现夜间服用降压药可改善夜间控制效果

2025-07-14

2025年7月14日